Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
Lilly's Mounjaro to cost 2,200 Danish crowns per month
Wegovy's price ranges from 1,313 to 2,353 crowns per month
Denmark's public health system does not reimburse weight-loss drugs
COPENHAGEN, Oct 24 (Reuters) -Lilly LLY.N will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals group Novo Nordisk NOVOb.CO.
The two drugmakers are the first-to-market with highly effective obesity treatments, a booming business that could be worth $150 billion in annual global sales by the early 2030s, according to some analysts.
In Denmark, Lilly is up against Novo whose drug Wegovy has seen a global whirlwind success that made the Danish group Europe's most valuable company and boosted the national economy.
Both Mounjaro and Wegovy are cleared for weight loss in combination with a reduced-calorie diet and increased physical activity, and come with added health benefits alleviating many problems linked to excess weight.
The price would be roughly 2,200 Danish crowns ($318.5) per month, a Lilly spokesperson told Reuters.
The monthly price of Wegovy varies from 1,313 crowns for a starter dose, to 2,353 crowns for the maximum maintenance dose, according to the website of the Danish medicines agency.
The number of users of Wegovy in Denmark increased from around 60,000 in January to 90,000 in August, which corresponded with 713,950 injection pens in the first eight months of this year, data from the Danish Health Data Authority showed.
In Denmark, a country of roughly 6 million people, around 19% of the population has a body mass index (BMI) of 30 or above.
The public health care system does not generally reimburse weight-loss drugs and the country's largest private health insurer, which covers roughly half the population, stopped paying for such drugs in 2023 due to high demand.
Mounjaro was launched in Sweden and Finland last week and will soon be launched in Norway, the spokesperson said. Elsewhere in Europe, the drug has also been introduced in the UK, Poland, Spain, Switzerland and Germany.
($1 = 6.9076 Danish crowns)
Reporting by Stine Jacobsen and Louise Breusch Rasmussen
Editing by Tomasz Janowski
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
